ChuaIS, FrattE, HoJJ, et al.: Primary addiction medicine skills for hospice and palliative medicine physicians: A modified Delphi Study. J Pain Symptom Manage, 2021; 62:720–729.
2.
MerlinJS, KhodyakovD, ArnoldR, et al.: Expert panel consensus on management of advanced cancer–related pain in individuals with opioid use disorder. JAMA Netw Open, 2021; 4:e2139968.
3.
JonesKF, O'Reilly-JacobM, and TierneyM: Eliminating the buprenorphine DEA X waiver is critical to promote health equity. Nurs Outlook, 2022; 70:5–7.
4.
JonesKF, HoJJ, SagerZ, et al.: Adapting palliative care skills to provide substance use disorder treatment to patients with serious illness. Am J Hosp Palliat Med, 2022; 39:101–107.
5.
VowlesKE, McEnteeML, JulnesPS, et al.: Rates of opioid misuse, abuse, and addiction in chronic pain: A systematic review and data synthesis. Pain, 2015; 156:569–576.
6.
BeaucheminM, DorritieR, and HershmanDL: Opioid use and misuse in children, adolescents, and young adults with cancer: A systematic review of the literature. Support Care Cancer, 2021; 29:4521–4527.
7.
MackeyK, VeazieS, AndersonJ, et al.: Barriers and facilitators to the use of medications for opioid use disorder: A rapid review. J Gen Intern Med, 2020; 35(Suppl 3):954–963.
8.
GabbardJ, JordanA, MitchellJ, et al.: Dying on hospice in the midst of an opioid crisis: What should we do now?. Am J Hosp Palliat Med, 2019; 36:273–281.
9.
MorylN, and MalhotraVT: A case for palliative care and addiction specialists collaboration and joint research. JAMA Netw Open, 2021; 4:e2143436.
10.
MerlinJ, YoungS, ArnoldR, et al.: Managing opioids, including misuse and addiction, in patients with serious illness in ambulatory palliative care: A qualitative study (GP765). J Pain Symptom Manag, 2020; 60:284.
11.
NiaziSK, SpauldingA, BrennanE, et al.: Mental health and chemical dependency services at US Cancer Centers. J Natl Compr Cancer Netw, 2021; 19:829–838.
12.
LagisettyPA, RossR, BohnertA, et al.: Buprenorphine treatment divide by race/ethnicity and payment. JAMA Psychiatry, 2019; 76:979–981.
13.
HaffajeeRL, BohnertASB, and LagisettyPA: Policy pathways to address provider workforce barriers to buprenorphine treatment. Am J Prev Med, 2018; 54(6Suppl 3):S230–S242.
14.
WakemanSE, LarochelleMR, AmeliO, et al.: Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open, 2020; 3:e1920622.
15.
GertnerAK, RobertsonAG, PowellBJ, et al.: Primary care providers and specialists deliver comparable buprenorphine treatment quality. Health Affairs, 2020; 39:1395–1404.
16.
FiellinDA, BarryDT, SullivanLE, et al.: A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med, 2013; 126:74.e11–e17.
17.
ConneryHS: Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry, 2015; 23:63–75.
18.
ThomasCP, DoyleE, KreinerPW, et al.: Prescribing patterns of buprenorphine waivered physicians. Drug Alcohol Depend, 2017; 181:213–218.
National Academies ofSciences, Engineering, and Medicine: Pain Management for People with Serious Illness in the Context of the Opioid Use Disorder Epidemic: Proceedings of a Workshop. Washington, DC: The National Academies Press, 2019.
